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Background: Sapropterin dihydrochloride effectively lowers plasma phenylalanine (Phe) for at least a third of
phenylketonuria (PKU) patients, with potential for increased dietary Phe tolerance and decreased medical food
requirement.
Objective: To investigate long-term quality of life (QOL) in patients with phenylketonuria (PKU) who took sapropterin
(BH4, Kuvan®) for up to one year.
Methods: 37 PKU patients, ages 10–49 years, were asked to complete a PKU-specific self-report QOL questionnaire
(QOLQ) at baseline, 1, 4, 8, and 12 months. Questions were scored on a 5-point Likert scale under 5 sub-sections
measuring Impact, Worries, Satisfaction, Support, and General wellbeing in relation to PKU. Responders with a
plasma Phe decrease ≥ 15% after 1 month on sapropterin remained on the drug; Nonresponders ceased sapropterin
after the trial month. Responders able to relax medical diet and maintain plasma Phe control were classified as
Definitive; Responders unable to relax medical diet were classified as Provisional. All patients were routinely
monitored by a registered dietitian. Data was analyzed in SPSS 19.0 using regression techniques.
Results: Of 17 Responders, 11 could maintain adequate Phe control on a less restrictive diet. One year mean
Impact sub-score trends improved significantly for all sapropterin response groups, with greatest improvement
among Definitive Responders (p < 0.0001). Satisfaction sub-scores also improved for Definitive Responders (p = 0.001).
Trends for Total QOL score improved significantly over time for both Definitive (p = 0.001) and Provisional Responders
(p = 0.028). Improvements in Definitive Responder scores were associated with increased Phe tolerance (Impact:
p < 0.0001, Satisfaction: p = 0.022, Total QOL: p = 0.005) and MF adjustment (Satisfaction: p = 0.014, Total QOL: p = 0.026).
Other sub-section scores remained steady, unaffected by sapropterin response or diet modification.
Conclusion: Increased Phe tolerance and reduced MF requirement in sapropterin Definitive Responders improves QOL
perception across one year, specifically for life impact and satisfaction.
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Phenylketonuria (PKU) is a recessively inherited inborn
error of metabolism. Impaired phenylalanine hydroxylase
(PAH) activity in PKU inhibits the effective metabolism of
its phenylalanine (Phe) substrate. Blood Phe concentrations
can therefore increase to neurotoxic concentrations. Since* Correspondence: rsingh@emory.edu
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reproduction in any medium, provided the orPhe is ubiquitously found in most food sources, to prevent
neurologic damage induced by high Phe concentrations,
those with PKU must follow a strict low Phe diet through-
out their lives and consume a Phe-free amino acid rich
medical food as their primary source of protein nutrition.
This diet treatment strategy involves daily monitoring of
medical food and Phe intake so that patients with PKU can
maintain plasma Phe concentrations within the safe thera-
peutic threshold of 100–360 μmoles/L.
Although newborn screening has enabled dietary treat-
ment for PKU to begin during early infancy, therebyl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developmental and cognitive disability, the dietary regi-
men for PKU can be rigorous, expensive, and socially
burdensome to both families and patients [1,2]. In par-
ticular, patients transitioning into adolescence and adult-
hood will demonstrate decreased dietary compliance and
plasma Phe concentrations increased beyond the thera-
peutic range [3,4]. Although the consequences are not as
severe as during infancy and young childhood, this non-
compliance has been shown to lead to neurological seque-
lae such as increased risk of mood disorders [5], attention
deficits [6,7], impairments to executive functioning [8-10],
school performance and achievement [11], and social diffi-
culties [12], issues which can certainly impact QOL. Past
studies have implicated both high plasma Phe concentra-
tions as well as the strict medical diet in reduced quality of
life (QOL) for patients with PKU [13,14].
Sapropterin dihydrochloride, a pharmaceutical form of
the chaperone PAH cofactor tetrahydrobiopterin (BH4),
not only lowers plasma Phe concentrations for up to half
of patients with PKU [15], but many of these sapropterin
responders are reported to also experience notable
increases to dietary Phe tolerance, allowing for a less
restricted diet as long as they remain on the pharmaceut-
ical [16]. This study is the first to evaluate QOL in a com-
bined adolescent and adult cohort of patients with PKU
for one year after initiating sapropterin. Our objective
was to determine if decreased plasma Phe and increased
dietary Phe tolerance induced by sapropterin would im-
prove self-reported QOL in adolescent and adult patients
with PKU.
Methods
Study design and patient enrollment
Patients 10 years of age and older with PKU who planned
to start sapropterin dihydrochloride (Kuvan, BioMarin
Pharmaceutical Inc.) were asked to volunteer for a 1 year
prospective cohort study in which QOL would be evalu-
ated in the form of a self-report questionnaire. All
patients were recruited through the Emory University
Genetics Clinic in Atlanta Georgia. Enrollment lasted
from October 2008 through October 2009. Participants
were asked to complete the questionnaire prior to start-
ing sapropterin as well as at 1, 4, 8, and 12 months
thereafter. Blood was collected during corresponding
clinic visits for evaluation of plasma amino acids (PAA)
(Biochrom 30 HPLC Amino Acid Analyzer) (μmoles/L).
Three day food records were collected and analyzed by
a licensed registered dietitian. Food records were ana-
lyzed using Nutrition Data System for Research (NDSR)
to calculate average daily intake of energy (kcals),
Phe (mg), and protein (g). Reported intake of medical
food protein and dietary Phe was assessed in parallel with
the patients’ medical food protein prescription (g/day)and dietary Phe tolerance (mg/day), with the dietitian
adjusting as needed.
Preliminary response to sapropterin was determined
after one month of taking 20 mg/kg/day of the medica-
tion. Patients were instructed to continue with current
medical food and dietary Phe practices to ensure that
observed changes in plasma Phe were due to sapropterin
response rather than dietary manipulation. Patients were
classified as Preliminary Responders if plasma Phe de-
creased by at least 15% and continued on sapropterin
throughout follow-up. Patients without this decline in
plasma Phe were classified as Non-responders and dis-
continued the medication. All patients met with a regis-
tered dietitian during clinic visits. Non-responders were
encouraged to continue with their prescription diet plan,
while Preliminary Responders were provided Phe chal-
lenge and assessed for decreased medical food require-
ment. In agreement with criteria published by Singh and
Quirck [16], Preliminary Responders who could maintain
plasma Phe below the 360 umol/L therapeutic threshold
while increasing Phe tolerance and decreasing medical
food intake were determined to be Definitive whereas
Provisional Responders could not increase Phe or lower
medical food without compromising plasma Phe.
Patients provided written informed consent, or the
legal guardian’s written informed consent with age ap-
propriate patient verbal or written assent, prior to study
participation. Study protocol and informed consent pro-
cedures were approved by the Emory University institu-
tional review board (IRB). Inclusion criteria were a
diagnosis of PKU, minimum age of 10 years, and intent
to begin sapropterin as a treatment for PKU. Exclusion
criteria were having had biopterin therapy within 8 weeks
prior to study involvement, pregnancy or planning to be-
come pregnant, and literacy or comprehension difficulties
that would limit patient ability to provide informed con-
sent or complete the QOL questionnaire.
Quality of life questionnaire
The QOL questionnaire selected for this investigation, the
PKU-QOLQ, was developed to evaluate QOL parameters
specific to the experience of living with PKU. The PKU-
QOLQ is patterned after the validated juvenile diabetes
QOL questionnaire [17] and has been shown to predict
positive adaptive outcome in a cohort of adolescent females
with PKU [18]. The adapted PKU-QOLQ consists of five
quantitative subsections, each with a subset of numbered
questions that can be answered on a five-point Likert scale
(subsections and scoring ranges are described in Table 1).
Subsections evaluated 5 areas in which PKU could influ-
ence quality of life: impact of PKU on life quality, PKU re-
lated life worries, satisfaction with life and medical
management, sense of support from social network and
clinical community, and perspective on general well-being.
Table 1 Baseline PKU-QOL total score and sub-score characteristics
QOL Scoring
Mean ± SD Range n scores >mid-score Min-Max Mid-score
Scoring total (n = 34) 206 ± 29 109 to 246 32 51-255 153
Impact (n = 35) 71 ± 11 31 to 85 32 18-90 54
Worries (n = 35) 44 ± 8 13 to 50 33 10-50 30
Satisfaction (n = 35) 30 ± 7 15 to 40 26 8-40 24
Support (n = 34) 18 ± 3 10 to 20 30 4-20 12
General well-being (n = 34) 44 ± 8 30 to 54 29 11-55 33
n is the number of returned questionnaires with completed sections at baseline.
Minimum score: Lowest score possible if all answers in section scored a 1. Maximum score: Highest score possible if all answers in section scored a 5. Mid-score: If
all answers in a section scored a 3.
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often, sometimes, very seldom, and never”. For Satisfaction
and General sections, 1–5 Likert scale choices were “very
unsatisfied, somewhat unsatisfied, neither, somewhat satis-
fied, very satisfied”. Subscores for the quantitative subsec-
tions were combined into a total QOL score.
Statistical analysis
Study sample size was determined a-priori using SPSS
SamplePower 2.0 software. SamplePower’s sample size
and power analysis technique utilize Cohen’s calculations
for determining effect size and study power [19]. For this
investigation, an effect size of 1.22 was calculated from
an r2value of 0.55 found in a 2008 paper which showed
association between diet related plasma Phe improve-
ments and quality of life in PKU patients [13]. Thus, for
this study, a minimum sample size of 18 was determined
to be sufficient for a power of 0.8 with α = 0.05, and a
maximum of 5 covariates in linear models.
Statistical analysis of final data was completed
using SPSS 19.0. Baseline analysis of variable associ-
ations with QOL scores utilized Pearson correlation
and multivariate linear regression. Cox regression
survival analysis was used to investigate the impact
of baseline variables on attrition. ANCOVA by gen-
eralized linear method was used for analysis across
groups between baseline and one month. Mixed lin-
ear regression using an unstructured variance-
covariance type model was used to evaluate trends
across one year of follow-up since the method is ro-
bust in circumstances of unbalanced longitudinal
data [20]. When relevant, mixed models were ad-
justed for significant variation in intercepts or
slopes. Variables evaluated for association with QOL
outcomes include age, gender, physical activity level
(scored on a 1–5 Likert scale of low to high physical
activity), income, education, family marital status,
prescribed medical food protein, dietary Phe toler-
ance, plasma amino acids, and sapropterin response.
All analyses were two-tailed with α = 0.05.Results
Demographics, sapropterin response, and attrition
Thirty-seven male and female patients, age 10–49 years
(mean ± SD: 22.1 ± 9.4) enrolled in the study. Baseline
demographic data is portrayed in Table 2. At one month,
36 patients returned, with 17 classified as preliminary
Responders and 19 as Non-responders. Of the prelimin-
ary Responders, Phe challenge revealed 11 to be Defini-
tive and 6 to be Provisional by the study’s fourth month.
Seven of the Non-responders were lost to follow-up be-
fore the study year was complete. Support sub-scores at
baseline, but no other QOL outcomes, had a positive
correlation with length of time Non-responders remained
in the study (r = 0.45, p = 0.005). Single marital status was
also associated with higher attrition in Non-responders
(p = 0.037). Plasma Phe, dietary Phe, medical food intake,
age, gender, income, and education level were not asso-
ciated with attrition. Of the 29 patients who completed
the long-term QOL study, 8 failed to return the PKU-
QOLQ one or more times during the study while 2 others
did not complete all subsections of the PKU-QOLQ on
one or more occasions.
QOL at baseline
Table 1 describes the average QOL scores, and scoring
ranges, for the PKU cohort at baseline. Total and sub-
scores averaged high, with at least 74% of participants
having baseline sub-scores above the mid-score and 94%
having a total QOL score above mid-score.
Total QOL score and all sub-scores other than Support
sub-score were inversely correlated with age (Table 3); as-
sociations with QOL scores, except for Support sub-score,
are therefore age adjusted. Plasma tyrosine was inversely
associated with Worries sub-score (p = 0.025) at baseline
but with no other QOL scores. Self reported physical activ-
ity level had a positive correlation with General well-being
sub-score (p = 0.018), while patients diagnosed with one or
more psychiatric disorders (ie: depression, anxiety, bipolar
disorder) reported lower Satisfaction scores (p = 0.028)
(Figure 1). Plasma Phe, prescribed diet, marital status,







Adolescent (10–19) 19 (51%)
Adult (20+) 18 (49%)
3 pairs of biological siblings 6 (16%)
Neuropsychiatric and Behavioral diagnoses –
No diagnosis 29 (78%)
ADHD 4 (11%)
Other (Depression, Bipolar, Anxiety) 4 (11%)





‡Marital status represents participants themselves age 19+, and of the legal
guardians for patients <19 years.
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line QOL scores. There were also no differences in baseline
PKU-QOL scores among prospective sapropterin response
groups. Controlling for same-household siblings did not
affect results.
QOL after 1 month of sapropterin
Characteristic of preliminary response to sapropterin,
plasma Phe significantly dropped (p = 0.008) after the
first month for 47% of study patients (Figure 2).Table 3 Baseline age-adjusted correlations of PKU-QOL scores
Impact Worries
Age (years) -.37* -.35*
(−.63, -.04) (−.61, -.02)
Plasma Phe (μmoles/L) NS NS
Plasma Tyrosine (μmoles/L) NS -.39*
(.07, .64)
Phe tolerance (mg/day) NS NS
MF protein Rx (g/day) NS NS
Physical activity NS NS
Psych/Behavior diagnosis‡ NS NS
Pearson coefficient (95% CI).
*P < .05, **P < .01, ***P < .001.
CI = Confidence Interval, Rx = Prescription, MF =Medical food.
NS = Not statistically significant.
‡: Psychological and behavior diagnosis dummy coded in SPSS: 1 = no diagnosis, 2However, no statistically significant change in PKU-
QOL scores occurred within or between Responders and
Non-responders from baseline to 1 month, even when
controlling for later determined Definitive and
Provisional response classification.QOL during 1 year
Baseline associations of age and physical activity with
QOL scores were unaltered in the long-term analysis
and were thus controlled for in relevant mixed regres-
sion models. Although plasma tyrosine was inversely asso-
ciated with Worries sub-scores at baseline, the association
was not significant long-term regardless of sapropterin
response classification. The impact of psychiatric or
ADHD status on long-term QOL outcomes could not
be determined due to the attrition within those smaller
categories.
There were no statistically significant differences be-
tween sapropterin response groups in PKU-QOL scores
during 1 year of follow-up, however significant within
group changes did occur. All response groups demon-
strated a trend towards improved Impact sub-scores, with
Definitive Responders experiencing the greatest improve-
ment (p < 0.0001) compared to Provisional Responders
(p = 0.01) and Non-responders (p = 0.05) (Figure 3B).
Trends for Satisfaction sub-scores increased significantly
for Definitive Responders only (p = 0.001) (Figure 3A),
while Worries, Support, and General well-being sub-scores
did not change significantly, irrespective of sapropterin re-
sponse. Trends in Total QOL scores significantly improved
for both Definitive (p = 0.001) and Provisional Responders
(p = 0.028) (Figure 3C). Although Non-responders experi-
enced a modest improved trend in Impact sub-scores, totalSatisfaction Support Generally Total score
-.48** NS -.55** -.58***
(−.70, -.17) (−.75, -.26) (−.77, -.30)
NS NS NS NS
NS NS NS NS
NS NS NS NS
NS NS NS NS
NS NS .41* NS
(.08, .66)
-.38* NS NS NS
(−.63, -.05)
= ADHD diagnosis, 3 = psychiatric diagnosis (Bipolar, Depression, Anxiety).
p=0.028
not significant
Figure 1 Baseline Satisfaction sub-scores (mean ± 1 SD) across
PKU patients with and without psychiatric diagnosis (Depression,
Anxiety, Bipolar) and ADHD. P-values are Bonferroni adjusted for
multiple comparisons.
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cantly over one year.
Association of plasma Phe, Phe tolerance, and prescribed
medical food with long-term QOL scores
Table 4 details the significance of regressed associations
between long-term QOL scores and the modifiers
plasma Phe, dietary Phe tolerance, and prescribed med-
ical food protein.
Significant long-term declines in plasma Phe among
Definitive Responders (p = 0.002) (Figure 2) was associ-
ated with linear increases to Satisfaction (p < 0.0001),













 By 1 month: p=0.004 
Trend long-term: p=0.038
At 1 month: p=0.048 
Trend long-term: NS
NS at 1 month and long-term
Figure 2 Plasma Phe (mean ± 1 SD) of sapropterin response
groups across 5 study visits. Clustered bars represent study visits
at Baseline, 1, 4, 8, and 12 months respectively. NS = Not significant.Interestingly, plasma Phe had a direct association with
Impact sub-scores in Non-responders (p = 0.038), though
was not associated with Provisional Responder’s QOL
scores.
Observed increases to dietary Phe tolerance inherent
to Definitive Responder status (Figure 4A) were associ-
ated with improved trends in Impact (p < 0.0001), Satis-
faction (p = 0.025), and Total (p = 0.005) QOL scores
across one year. Phe tolerance, remaining unchanged for
Provisionals and Non-responders, had a significant positive
association with Impact subscores for Non-responders
(p = 0.012), although not for Provisional’s (p = 0.062).
Significant reductions to prescribed medical food pro-
tein (g/day) for Definitive Responders (Baseline Mean ±
SD: 51.8 ± 20.8, 1 year: 9.0 ± 12.5) (p < 0.0001) (Figure 4B)
accommodated increases to protein and energy intake
from intact food sources within the limits of effective
Phe control. Reductions to medical food Rx in Definitive
Responders was associated with better Satisfaction sub-
scores (p = 0.014) and total QOL score (p = 0.026). For
the undifferentiated PKU cohort, higher Impact scores
had a long-term linear association with lower medical
food prescriptions (p = 0.04), but the association was
not maintained once stratified by sapropterin response
groups. No other QOL scores were influenced by medical
food prescription long-term, irrespective of sapropterin
response.
Discussion and conclusion
The observation that most of our study patients had
QOL scores exceeding the mid-score, with high means
at both baseline and throughout the study (Table 1,
Figures 3A-C), is consistent with other research demon-
strating good QOL in adults, adolescents, and young
children with PKU when compared to non-PKU refer-
ence samples [12,21-23], although Cotungo’s 2011 study
did discover lower parent reported QOL scores for chil-
dren with PKU compared to a non-PKU reference group
[21]. Since the focus of our study was to investigate
sapropterin’s influence, along with relevant dietary modi-
fications, on self-reported QOL within a cohort living
with PKU, as opposed to comparing QOL in PKU to that
of non-PKU populations, our results do not conflict with
the Cotungo’s 2011 pediatric results. The high baseline
scores of our study patients, however, may create a ceil-
ing effect that inhibits observation of long-term changes;
in essence, improvements to quality of life may not be as
measurable when quality of life is already near the upper
scale limits. This phenomenon may be a reflection of
patient adaptation, in an emotional and psychological
sense, to their disorder [24,25] or it may indicate a need
for improved sensitivity in the questionnaire’s QOL scale.
In addition, 83% of the cohort reported Phe intake above








Figure 3 (A,B,C): Impact and Satisfaction sub-score (A and B) and total QOL (C) trends across one year. *p < 0.05, **p < 0.01, ***p < 0.001.
p-values for longitudinal trends are age adjusted. Y-axis begins at minimum score.
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Phe tolerance could be attenuated in patients already
consuming liberal amounts of dietary Phe. This may ex-
plain the lack of observed change in the PKU-QOL sub-
scores for Worries, Support, and General well-being.
Even so, we were able to detect improvements in
Impact, Satisfaction, and Total QOL outcomes across one
year in our patient sample, most pronounced in those PKUTable 4 Variable interactions‡ with QOL scores across time fo
Impact
D N P All D
Phe tolerance (mg/day) (+)*** (+)* NS (+)*** (+
MF protein Rx (g/day) NS NS NS (−)* (−
Plasma Phe (μmoles/L) (+)** (+)* NS (+)** (+)
*p < 0.05, **p < 0.01, ***p < 0.001.
‡Interaction defined as “variable*time*response category” in longitudinal mixed reg
†Results for Worries, Support, and Generally sub-scores not included since no signif
(+) indicates positive association, (−) indicates negative association. NS = not statisti
D: Definitive Responders, N: Non-responders, P: Provisional Responders, All: Complepatients on sapropterin able to liberalize diet. This may
seem contrary to Ziesch’s study where no changes in health
related QOL were observed after 3 months in pediatric
patients with PKU provided sapropterin, irrespective of
ability to liberalize diet while maintaining good blood
Phe control. However, our analysis of a larger adolescent &
adult cohort evaluated QOL multiple times across a full
year, allowing us to observe the gradual long-term positiver sapropterin response groups and whole study sample †
Satisfaction Total score
N P All D N P All
)* NS NS (+)* (+)** NS NS (+)*
)* NS NS (−)* (−)* NS NS NS
*** NS NS (+)** (+)** NS NS (+)*
ression analysis.

























































Figure 4 (A and B): Mean (± 1 SD) Phe tolerance (mg/day) and prescribed medical food protein (g/day) of sapropterin response
















Intake ≤ PT 0.1-2x > PT >2X above PT
Baseline dietary Phe adherance  retrospectively 
stratified by sapropterin response. Values are n.
Definitive Responders
Figure 5 Baseline dietary Phe compliance of patients with PKU. ‡Dietary Phe compliance defined as patient-reported Phe intake in excess of
Phe tolerance (PT) (mg/day). One patient with undetermined baseline Phe tolerance omitted from figure.
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beneficial outcomes were particularly evident in Definitive
Responders. Of important distinction also is our use of a
questionnaire tool specifically developed for measuring
QOL in individuals with PKU. A lack of available QOL
tools specific to inborn errors diagnoses was acknowledged
by Ziesch as a possible limitation in his QOL study [22].
Although the PKU-QOLQ is still in the process of valid-
ation for males and other age groups, it proved highly
effective at assessing QOL in our study sample, when con-
trolling for age, with no observed gender differences in
scoring outcomes. Internal consistency was considered
good, with Cronbach Alpha > 0.8 for the questionnaire and
its subsections, as well as across age and gender groups
(Table 5). Hence, the differences in our study design, tools,
and patient cohort offers the best explanation for the dis-
crepancy between our study and Ziesch’s.
An interesting observation in this analysis was that dif-
ferences in Phe tolerance were not associated with QOL
outcomes at baseline, yet increased Phe tolerance over
the course of one year in Definitive Responders was sig-
nificantly associated with improved QOL outcomes. The
lack of baseline association may be due to the psycho-
emotional adaptation of these patients to the constraints
of PKU diagnosis, as discussed earlier, particularly since
patients have lived with the condition since birth. How-
ever, a fast dramatic increase in Phe tolerance that is sus-
tained as a result of sapropterin treatment could boost
QOL self-perception when measured over time. Whether
that improvement in QOL can be sustained, or whether
patients will habituate to their higher Phe tolerance
with QOL gradually returning to baseline, remains to
be seen in future analysis where follow-up extends beyond
one year.
Also noteworthy is that Non-responders and Provisional
Responders were without significant change to Phe toler-
ance or formula dependence, yet had significant improve-
ment to their Impact QOL scores. The trend seen in
Provisionals and Non-responders was modest compared
to the improved QOL observed in Definitive Responders,
but being statistically significant still deserves explanation.
The modest QOL increase in these two groups may
be due to a Hawthorne effect: essentially, the patients’Table 5 Cronbach Alpha analysis of PKU QOL questionnaire
No. of questions Overall alpha Alpha for ad
Impact 18 0.87 0.84
Worries 10 0.91 0.86
Satisfaction 8 0.88 0.87
Support 4 0.88 0.91
General well-being 11 0.90 0.90
Total questionnaire 51 0.95 0.94answers to QOL questions improved over time as a result
of monitoring within the study parameters. Additionally,
the QOL scores could reflect patient emotional benefit to
increases in medical surveillance and monitoring, since all
study subjects received more frequent personalized med-
ical attention throughout the study year. A placebo effect
in the case of Provisional Responders is also possible.
Patients within this group anecdotally reported the benefit
they felt sapropterin had on their lives even though their
diets were not significantly liberalized. Therefore, patient
self-reports of life benefits and improved emotional out-
comes while on sapropterin should be considered object-
ively when these patients meet the criteria for provisional
response [16]. If while on sapropterin patients are not
benefitting from improved Phe control, nor demonstrating
improved Phe tolerance, the clinical benefit of sapropterin
in their PKU management plan should be scrutinized,
particularly since impact on QOL would most likely be
minimal.
Study results indicate baseline Support scores, in
addition to other factors such as marital status and
sapropterin response classification, could effectively pre-
dict long-term attrition within our PKU study cohort. In
fact, sense of emotional support had the strongest rela-
tionship with study attrition, such that the amount of
weeks spent in the study could be predicted by how high
the support scores were at baseline, particularly in Non-
responders where most of the attrition occurred. Inter-
estingly, the Support section represents the smallest
question cluster in the QOLQ. There are only 4 queries
which ask about support received from the person’s
family, friends, medical team, and nutrition team. An im-
provement in just one or two of these support aspects
could dramatically reduce attrition risk in future studies,
thus it may be worthwhile to ensure patients are pro-
vided an emotionally supportive clinical environment
from their very first appointment when long term follow-
up is indicated.
In agreement with other QOL studies, our analysis re-
vealed an inverse association between age and QOL
scores [26-28], thereby stressing the need to control for
age when evaluating QOL differences in clinical groups,
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when evaluating QOL, as our study indicated.
Due to several adult PKU study patients being neither
employed nor in school, two work/school questions were
frequently skipped. Modifications to the PKU-QOLQ
may be necessary to accommodate this circumstance in
adults, however for this study we resolved the issue by
eliminating those two specific questions from final
scoring and analyses.
Our study focused on patient self-reported QOL only;
however, improved QOL outcomes may also occur in
parents, caregivers, spouses, or other family members
when an individual with PKU is able to increase dietary
freedom due to a new treatment, such as sapropterin.
Though our clinicians have received many positive anec-
dotal reports from family members and caregivers of
sapropterin Responders (both Definitive and Provisional), a
formal analysis is needed to determine measurable QOL
benefits to these family members and caregivers. Such an
analysis was beyond the scope of this investigation but
would be a worthwhile pursuit for future study.
The present study results provide additional opportun-
ity to assist patients with PKU in areas where they report
feeling most challenged or discouraged from a social-
medical perspective. The information gleaned can assist
with technicalities of adjusting therapeutic protocols as
patients gain access to emerging treatment options, such
as sapropterin, which may offer more dietary freedom,
as well as with planning of long term clinical studies. In
this respect, patients can receive the emotional, medical,
and nutritional support they need for effective lifelong
management of their disorder.Conclusion
Self-reported quality of life measured high on average in
adolescents and adults with PKU. Nevertheless, marked
improvements occurred in the QOL areas where impact
on various aspects of life and self-sense of satisfaction were
measured. Improvements were most dramatic for patients
who experienced increased Phe tolerance while taking
sapropterin. These improvements were accomplished while
maintaining good Phe control in the majority of Definitive
Responders. Non-responders and Provisionals, who had no
increase in Phe tolerance, still demonstrated modest im-
provements to QOL during the study, albeit to a lesser ex-
tent than Definitive Responders. Aspects of general well
being, sense of social support, and worries in relation to
PKU and life were not associated with sapropterin re-
sponse classification, Phe tolerance, medical food prescrip-
tion, or PAA during the long-term study.
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